Sanofi and Teva Pharmaceutical Industries announced positive long-term maintenance data from the RELIEVE UCCD LTE study evaluating duvakitug, an investigational monoclonal antibody targeting TL1A, for the treatment of ulcerative colitis and Crohn's disease. The phase 2b long-term extension trial demonstrated durable clinical and endoscopic efficacy over a 44-week maintenance period among patients who achieved initial response during induction therapy, with sustained remission rates ranging from 47-58% in ulcerative colitis and 41-55% in Crohn's disease across tested dosages.
The maintenance data reinforces the therapeutic potential of TL1A inhibition in inflammatory bowel disease management, with the drug demonstrating consistent safety and tolerability outcomes aligned with previous trial phases. The durable efficacy observed throughout the extended follow-up period provides a foundation for advancing duvakitug into ongoing phase 3 clinical development, as both companies pursue regulatory pathways for this treatment approach in moderate-to-severe IBD populations.
The results support the continued clinical development of the asset and represent progress toward addressing treatment options in ulcerative colitis and Crohn's disease, conditions characterized by chronic intestinal inflammation affecting millions of patients globally.